On August 13th, China's State Council issued a 24-point guideline covering six areas.

On 28 July, NHSA issued the "Notice on Providing Basic Medical Security for Urban and Rural Residents in 2023 by National Healthcare Security Administration, Ministry of Finance and State Taxation Administration".

According to the forecast of GHICapital, the market size of China's dPCR industry will still maintain a high growth rate from 2020 to 2024, and the market size will grow from 2.133 billion yuan to 7.011 billion yuan, at a CAGR of 34.65%.

On July 5th, the State Council Information Office held a series of press conferences covering the review and approval of medical devices, medical device regulation, innovative medical devices and other industry issues of concern.

Recently, the Tianjin Medical Products Administration issued the "Notice on the Demonstration and Promotion of the Unique Identification of Medical Devices".

In some areas with weak medical resources in China, it is difficult for the public to obtain quality medical services and have to seek treatment across provinces and regions, which is a heavy economic and time burden.

In recent years, the State Council, the Development and Reform Commission and other departments have issued policies to support and regulate the biomedical industry.

From March 15, China has officially announced the resumption of all kinds of visas, including tourist visas (L Visa), and visa-free policies have been reinstated.

Recently, the General Office of the State Council communicated Measures of Ministry of Commerce and the Ministry of Science and technology (MOST) for Further Encouraging Foreign Investment in Establishing Research and Development (R&D) Centers in China.

On October 17, 2020, the 22nd meeting of the Standing Committee of the 13th National People's Congress voted to adopt the Biosafety Law, which will come into force on April 15, 2021.